Acorda Therapeutics (ACOR) Tops Q2 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
Acorda Therapeutics Reports Second Quarter 2021 Financial Results
August 5, 2021 4:01 PM EDTINBRIJA® (levodopa inhalation powder) Q2 2021 net revenue of $6.4 million; 36% increase over Q2 2020 AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg Q2 2021 net revenue of $21.8 million Agreement to commercialize INBRIJA in Spain with Esteve Pharmaceuticals $69 million of convertible senior notes repaid
ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported its financial results for the second quarter 2021.
We were pleased to see a 36% increase in INBRIJA net sales in the second quarter of 2021 over the same period in 2020. We also saw increases in... More
